is part of the Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Materials technology company leads EU project to develop next-gen drug-eluting resorbable stents

A project to develop new biomaterials and arterial stents has been awarded €5.87 million by the European Union. Materials technology company Ceram will lead this research project that includes the collaboration of 14 academic and industrial partners. The ReBioStent project aims to develop multifunctional biomaterials for reinforced bioresorbable drug-eluting stents.

"At the end of this three-year project, the group will have developed novel materials and new bioresorable stents, helping to place the EU as a world leader in both biomaterials and stent design and development," says Dr. Xiang Zhang, Principal Consultant, Healthcare at Ceram. "After the first six to 12 months of [stent] implantation, there is clinically no need for permanent coronary scaffolding. Being able to produce a bioresorbable drug-eluting stent, using biomaterials that the project aims to develop, will be groundbreaking for the healthcare industry," says Zhang.

Ceram is currently working on other innovative materials and technologies for the medical sector, including inorganic controlled release and novel bioceramic materials and toughened ceramics and ceramic polymer hybrids for bone repair/replacement activities.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.